Phospho-NOS2 (Y151) Antibody

What is the biological significance of NOS2 phosphorylation at the Y151 site?

Phosphorylation at Y151 represents a specific post-translational modification of inducible nitric oxide synthase (iNOS/NOS2). This enzyme produces nitric oxide (NO), a versatile messenger molecule with diverse functions throughout the body. NO mediates tumoricidal and bactericidal actions in macrophages and plays crucial roles in inflammatory processes. NOS2 also possesses nitrosylase activity, mediating cysteine S-nitrosylation of cytoplasmic target proteins such as PTGS2/COX2. Phosphorylation at Y151 likely regulates these activities, potentially affecting NOS2's role in enhancing the synthesis of pro-inflammatory mediators such as IL6 and IL8 . Understanding this specific phosphorylation event provides insights into the regulation of NOS2 function in diverse physiological and pathological contexts.

How do Phospho-NOS2 (Y151) antibodies differ from total NOS2 antibodies in terms of experimental utility?

Phospho-NOS2 (Y151) antibodies specifically detect NOS2 protein only when phosphorylated at tyrosine 151, whereas total NOS2 antibodies recognize the protein regardless of its phosphorylation status . This distinction is crucial for researchers investigating:

• The activation state of NOS2 in specific contexts

• Signaling pathways that regulate NOS2 through Y151 phosphorylation

• Spatial and temporal dynamics of NOS2 phosphorylation

• Correlation between phosphorylation status and functional outcomes

The specificity of phospho-specific antibodies allows for precise analysis of this post-translational modification, enabling researchers to distinguish between the total pool of NOS2 and the functionally regulated phosphorylated subset.

What experimental applications are validated for Phospho-NOS2 (Y151) antibodies?

Based on the available products, Phospho-NOS2 (Y151) antibodies have been validated for several experimental applications:

Researchers should consult the specific product documentation for the most appropriate dilutions and validated applications for their particular antibody .

What critical sample preparation steps ensure optimal detection of phosphorylated NOS2?

Preserving the phosphorylation status of NOS2 is essential for accurate detection with Phospho-NOS2 (Y151) antibodies. The following protocols are recommended:

• Tissue collection and preservation:

  • Process samples immediately after collection

  • Flash-freeze tissues in liquid nitrogen or fix rapidly with appropriate fixatives

  • Store frozen samples at -80°C until analysis

• Extraction and lysis:

  • Include phosphatase inhibitors in all buffers

  • Maintain cold temperatures (4°C or below) during all processing steps

  • Use gentle lysis conditions to preserve protein modifications

• Special considerations for phospho-proteins:

  • Avoid repeated freeze-thaw cycles, as indicated in product documentation

  • For short-term storage and frequent use, store antibodies at 4°C for up to one month

  • For long-term storage, keep at -20°C in aliquots to prevent degradation

These precautions are critical as phosphorylation modifications are labile and can be rapidly lost during improper sample handling.

How should researchers validate the specificity of Phospho-NOS2 (Y151) antibody signals?

Rigorous validation is essential when working with phospho-specific antibodies. Recommended validation approaches include:

• Positive controls:

  • Use samples known to contain phosphorylated NOS2 at Y151

  • Consider cell lines or tissues with inflammatory stimulation that induces iNOS phosphorylation

• Negative controls:

  • Treatment with phosphatases to remove phosphorylation

  • Y151F mutant constructs (if available) that cannot be phosphorylated at this site

  • iNOS knockout or knockdown samples

• Specificity tests:

  • Peptide competition assays using the phosphorylated peptide immunogen

  • Cross-reactivity assessment - confirm antibody does not detect eNOS or nNOS

  • Compare staining patterns with total NOS2 antibodies

• Technical controls:

  • Secondary antibody-only controls to assess background

  • Isotype controls to identify non-specific binding

Proper validation ensures that experimental observations genuinely reflect the phosphorylation status of NOS2 rather than artifacts.

What are the optimal fixation and antigen retrieval methods for immunohistochemical detection of phospho-NOS2?

While specific optimization may be required for different tissue types, general recommendations include:

• Fixation:

  • 10% neutral buffered formalin for 24-48 hours

  • Alternatives include paraformaldehyde-based fixatives

  • Avoid overfixation which can mask phospho-epitopes

• Antigen retrieval:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Optimize timing (typically 10-20 minutes) and temperature

  • Allow slides to cool slowly to room temperature after retrieval

• Blocking:

  • Use 5% BSA or 5-10% normal serum from the species of the secondary antibody

  • Include 0.1-0.3% Triton X-100 for permeabilization if needed

  • Block for at least 1 hour at room temperature

• Antibody incubation:

  • Dilute primary antibody to recommended range (1:100-1:300 for IHC)

  • Incubate overnight at 4°C in a humidified chamber

  • Use appropriate detection system based on primary antibody host species

These protocols should be optimized for each specific experimental system to maximize signal-to-noise ratio.

How does phosphorylation at Y151 affect NOS2 cellular localization and protein interactions?

NOS2 typically localizes as discrete foci scattered throughout the cytosol, but in the presence of SPSB1 and SPSB4, it exhibits a more diffuse cytosolic localization . Phosphorylation at Y151 may influence these localization patterns and protein-protein interactions, particularly:

• Impact on complex formation:

  • As a component of the iNOS-S100A8/9 transnitrosylase complex, phosphorylation may regulate the selective inflammatory stimulus-dependent S-nitrosylation of GAPDH on 'Cys-247'

  • This may affect regulation of the GAIT complex activity and interactions with other targets including ANXA5, EZR, MSN, and VIM

• Research approaches to investigate localization effects:

  • Immunofluorescence microscopy comparing phospho-Y151 NOS2 with total NOS2

  • Co-immunoprecipitation studies with complex components

  • Live cell imaging with phospho-mimetic mutations (Y151D/E) versus phospho-dead mutations (Y151F)

  • Subcellular fractionation followed by Western blotting with phospho-specific antibodies

Understanding these interactions may provide insights into how phosphorylation regulates NOS2's diverse functions in inflammation and immune responses.

What signaling pathways regulate NOS2 Y151 phosphorylation in different cell types?

While the specific kinases and phosphatases that regulate Y151 phosphorylation are not explicitly described in the provided search results, investigators should consider:

• Potential regulatory pathways:

  • Inflammatory cytokine signaling pathways (TNF-α, IL-1β, IFN-γ)

  • Tyrosine kinase signaling cascades

  • Stress-activated protein kinase pathways

  • Bacterial or viral pathogen-associated molecular pattern (PAMP) recognition pathways

• Cell-type specific considerations:

  • Macrophages: Focus on pathways activated during polarization (M1/M2)

  • Hepatocytes: Examine cytokine and stress response pathways

  • Airway epithelial cells: Consider inflammatory and mechanical stress pathways

  • Chondrocytes: Examine cartilage-specific cytokine and mechanical regulation

• Experimental approaches:

  • Kinase inhibitor screens to identify responsible enzymes

  • Phosphoproteomics to identify co-regulated phosphorylation events

  • Time-course analysis following cell stimulation

  • siRNA/CRISPR-based knockdown of candidate kinases

Elucidating these regulatory mechanisms would provide valuable insights into how NOS2 activity is controlled in various pathophysiological contexts.

How does the phosphorylation status of NOS2 Y151 correlate with disease progression in inflammatory disorders?

NOS2 plays critical roles in inflammatory diseases, and its phosphorylation at Y151 may serve as a biomarker or functional regulator in disease processes:

• Potential disease contexts:

  • Chronic inflammatory conditions where NOS2 enhances pro-inflammatory mediators IL6 and IL8

  • Infectious diseases where NO mediates bactericidal actions

  • Cancer contexts where macrophage-derived NO has tumoricidal properties

  • Autoimmune disorders with dysregulated inflammation

• Research strategies:

  • Comparative immunohistochemistry of disease versus normal tissues

  • Correlation of phospho-Y151 levels with disease severity markers

  • Animal models with phospho-mimetic or phospho-dead NOS2 mutations

  • Therapeutic targeting of pathways regulating Y151 phosphorylation

• Tissue-specific considerations:

  • Liver pathologies (hepatitis, cirrhosis, hepatocellular carcinoma)

  • Retinal inflammatory diseases

  • Bone and cartilage disorders (arthritis, osteoporosis)

  • Pulmonary diseases involving airway epithelial cells

These investigations could identify novel therapeutic targets and biomarkers for inflammatory diseases.

What are common technical challenges when using Phospho-NOS2 (Y151) antibodies and their solutions?

Researchers frequently encounter several issues when working with phospho-specific antibodies:

• Low signal intensity:

  • Increase antibody concentration within the recommended range (1:100-1:300 for IHC)

  • Extend primary antibody incubation time (overnight at 4°C)

  • Enhance antigen retrieval conditions

  • Use signal amplification systems (e.g., tyramide signal amplification)

  • Verify phosphatase inhibitors are effective in preserving phosphorylation

• High background or non-specific staining:

  • Optimize blocking conditions (increase blocking time or agent concentration)

  • Dilute antibody appropriately (follow specific recommendations for each application)

  • Increase wash steps duration and number

  • Pre-absorb antibody with non-specific proteins

  • Verify secondary antibody compatibility and specificity

• Inconsistent results between experiments:

  • Standardize sample collection and processing protocols

  • Prepare antibody dilutions fresh for each experiment

  • Avoid repeated freeze-thaw cycles of antibody

  • Maintain consistent incubation times and temperatures

  • Use internal controls in each experiment

• Cross-reactivity concerns:

  • Verify antibody specificity using appropriate controls

  • Confirm the antibody does not cross-react with eNOS or nNOS

  • Consider species-specific optimization for cross-species applications

How can researchers quantitatively analyze phospho-NOS2 levels across different experimental systems?

Accurate quantification requires standardized approaches:

• Western blot quantification:

  • Use internal loading controls (housekeeping proteins)

  • Calculate phospho-NOS2/total NOS2 ratios to normalize for expression differences

  • Apply appropriate statistical methods for multiple comparisons

  • Use standard curves with recombinant phosphorylated proteins when available

• Immunohistochemistry quantification:

  • Apply consistent staining protocols across all specimens

  • Use automated image analysis software for unbiased quantification

  • Establish clear scoring criteria (intensity, percentage positive cells)

  • Include reference standards in each batch of staining

• ELISA-based quantification:

  • Follow recommended dilutions (1:10000)

  • Generate standard curves using known concentrations of phosphopeptide

  • Normalize to total protein concentration

  • Include technical replicates and quality controls

• Factors affecting quantitative analysis:

  • Sample preparation consistency

  • Antibody lot-to-lot variability

  • Detection system linearity range

  • Image acquisition parameters

Standardized quantification is essential for meaningful comparisons across experimental conditions and between different studies.

What experimental controls are essential when comparing phospho-NOS2 levels between different treatment conditions?

Robust experimental design requires comprehensive controls:

• Treatment-specific controls:

  • Vehicle control for each treatment

  • Time-matched controls for kinetic studies

  • Dose response curves to establish optimal treatment conditions

  • Positive controls (treatments known to induce Y151 phosphorylation)

• Technical controls:

  • Replicates (both biological and technical)

  • Randomization of sample processing order

  • Blinding of analysis when possible

  • Consistent timing of sample collection post-treatment

• Validation controls:

  • Parallel analysis with multiple techniques (e.g., WB and IHC)

  • Total NOS2 measurement alongside phospho-specific detection

  • Kinase inhibitor controls to verify pathway specificity

  • siRNA knockdown of NOS2 to confirm antibody specificity

• Data analysis controls:

  • Appropriate statistical tests based on data distribution

  • Multiple testing corrections for large datasets

  • Power analysis to ensure adequate sample size

  • Transparent reporting of all data points and outliers

These controls ensure that observed differences in phospho-NOS2 levels are biologically meaningful rather than technical artifacts.

What emerging technologies might enhance the study of NOS2 Y151 phosphorylation?

Several cutting-edge approaches could advance our understanding of this post-translational modification:

• Proximity-based techniques:

  • Proximity ligation assays to study interactions of phosphorylated NOS2

  • BioID or APEX2 proximity labeling to identify proteins interacting specifically with phospho-NOS2

  • FRET-based biosensors to monitor Y151 phosphorylation in real-time

• Advanced microscopy approaches:

  • Super-resolution microscopy to visualize subcellular localization

  • Live-cell imaging of phosphorylation dynamics using genetically-encoded reporters

  • Correlative light and electron microscopy to connect phosphorylation with ultrastructural features

• Systems biology methods:

  • Phosphoproteomics to place Y151 phosphorylation in broader signaling networks

  • Mathematical modeling of NOS2 regulation by phosphorylation

  • Multi-omics integration to connect phosphorylation to functional outcomes

• Genetic approaches:

  • CRISPR-based endogenous tagging of NOS2 for physiological studies

  • Knock-in phospho-mimetic or phospho-dead mutations to assess functional significance

  • Tissue-specific conditional expression systems for in vivo studies

These technologies could reveal new insights into the regulation and function of NOS2 Y151 phosphorylation in health and disease.

How might therapeutic targeting of pathways regulating NOS2 Y151 phosphorylation impact inflammatory diseases?

Understanding the kinases and phosphatases that regulate Y151 phosphorylation could lead to novel therapeutic approaches:

• Potential therapeutic strategies:

  • Small molecule inhibitors of kinases responsible for Y151 phosphorylation

  • Peptide-based inhibitors that block phosphorylation site accessibility

  • Targeted degradation of hyperphosphorylated NOS2

  • Cell type-specific delivery of modulators affecting phosphorylation

• Disease contexts for therapeutic exploration:

  • Chronic inflammatory conditions

  • Autoimmune disorders

  • Inflammatory cancers

  • Infectious diseases with hyperinflammatory components

• Considerations for drug development:

  • Specificity for NOS2 versus other NOS isoforms

  • Cell type-specific effects on phosphorylation

  • Temporal aspects of treatment to target disease phase

  • Combination approaches with existing anti-inflammatory therapies

• Biomarker potential:

  • Phospho-Y151 NOS2 as a predictive marker for treatment response

  • Monitoring phosphorylation status to assess disease activity

  • Companion diagnostics for phosphorylation-targeting therapeutics